Consun Pharmaceutical Group (FRA:C1P) Other Net Income (Loss) : €0.0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Consun Pharmaceutical Group Other Net Income (Loss)?

Consun Pharmaceutical Group's Other Net Income (Loss) for the six months ended in Dec. 2024 was €0.0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 was €0.0 Mil.

Consun Pharmaceutical Group's quarterly Other Net Income (Loss) declined from Dec. 2023 (€0.0 Mil) to Jun. 2024 (€0.0 Mil) and declined from Jun. 2024 (€0.0 Mil) to Dec. 2024 (€0.0 Mil).

Consun Pharmaceutical Group's annual Other Net Income (Loss) stayed the same from Dec. 2022 (€0.0 Mil) to Dec. 2023 (€0.0 Mil) but then declined from Dec. 2023 (€0.0 Mil) to Dec. 2024 (€-0.0 Mil).

Consun Pharmaceutical Group Other Net Income (Loss) Historical Data

The historical data trend for Consun Pharmaceutical Group's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Consun Pharmaceutical Group Other Net Income (Loss) Chart

Consun Pharmaceutical Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Net Income (Loss)

Get a 7-Day Free Trial

Consun Pharmaceutical Group Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

Consun Pharmaceutical Group Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.0 Mil.

Consun Pharmaceutical Group Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Consun Pharmaceutical Group's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Consun Pharmaceutical Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Consun Pharmaceutical Group Ltd (FRA:C1P) » Definitions » Other Net Income (Loss)

Traded in Other Exchanges

CPHGF:USA 01681:Hong Kong

Address

71, Dongpeng Avenue, Eastern section, Guangzhou Economic and Technological Development, Guangzhou, CHN

Website

https://www.chinaconsun.com

Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Consun derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.

Consun Pharmaceutical Group Headlines

No Headlines